News

Palantir Has a Hand in NIH’s Most Ambitious Health Initiative

By Julia Métraux, Mother Jones [cites CGS' Katie Hasson] | 07.07.2026

During his 2015 State of the Union address, then-President Barack Obama announced what he promised would be an ambitious public health project. “Tonight, I’m launching a new Precision Medicine Initiative to bring us closer to curing diseases like cancer and diabetes...

U.S. Federal

The Measured Listener

By Daniel Shanahan, Los Angeles Review of Books | 05.31.2026

This is the 15th installment in the Legacies of Eugenics series, which features essays by leading thinkers devoted to exploring the history of eugenics and the ways it shapes our present. You can read the first part here. The series...

U.S. States

These companies help parents try to pick their babies' traits. Experts are wary

By Rob Stein, NPR [cites CGS' Katie Hasson] | 05.06.2026

Justin Schleede reaches onto a black lab bench to pick up a tray of small plastic tubes.

"These are saliva...

Genetic Selection

The start-ups dreaming of creating genetically modified babies

By Alexandre Piquard, Le Monde [cites CGS' Katie Hasson] | 05.22.2026

"If proven to be safe, we believe preventive gene editing could be one of the most important health technologies of...

U.S. Federal

State deserves a share of stem-cell benefits

By admin San Francisco Chronicle | 12.09.2004
IT'S FAIR to ask -- as state Sen. Deborah Ortiz, D-Sacramento, did this week -- just what California will get...
Biotech & Pharma

Business and Politics Mix Badly in California

By Chris Nolan, eWeek | 12.09.2004
Stem cell research initiative could be a boon for science, but business leaders are eroding public support by holding closed-door...
Biotech & Pharma

Presentation at the Symposium, "The Next Four Years, the Biotech Agenda, the Human Future: What Direction for Liberals and Progressives?"

By Sheldon Krimsky | 12.09.2004

[summary]

I would like to focus on four points:

1) The discourse on science policy issues has been dominated by...

Civil Society

Race and the Biotech Agenda

By Dorothy Roberts | 12.09.2004

Perhaps the greatest danger posed by the biotech agenda is its power to intensify racial injustice in America. Not only...

Racial Justice

Introduction to "The Next Four Years, the Biotech Agenda and the Human Future"

By Richard Hayes | 12.09.2004

Introduction to The Next Four Years, the Biotech Agenda and the Human Future, New York, NY 

Text of opening...

Civil Society

Prop. 71's fine print contains surprises: Tightly written law leaves little room for oversight or changes

By Bernadette Tansey, San Francisco Chronicle | 12.08.2004

 

The $3 billion stem cell initiative that passed overwhelmingly last month holds surprises for voters who didn't read it...

Biotech & Pharma

Stem Cell Spending Fight Builds

By Megan Garvey, Los Angeles Times | 12.07.2004
A state senator is seeking legislative oversight for the bond money approved by voters for research. The initiative's author opposes...
Biotech & Pharma

Proposition 71 needs reform

By admin San Francisco Examiner | 12.07.2004
Examiner View

AS THE STATE prepares to start distributing grants and loans authorized by Proposition 71, the $3 billion stem...
Biotech & Pharma